45 minutes
2018 was a record year for biotech IPOs, the XBI hit an all-time high in August, and the FDA approved a record number of novel drugs. What will 2019 bring after late 2018’s many signals of a slowing market? Will M&A pick up? Can new IPOs continue at last year’s pace? How will public markets respond? Investment bankers, private equity, and industry leaders peer into their crystal ball to predict the financial outlook for the next few years.


Barbara Dalton - Senior Managing Partner, Pfizer Ventures; Vice President, Pfizer Inc
Bruce Booth - Partner, Atlas Ventures
Christine Brennan - Partner, MRL Ventures Fund
Kathy Bergsteinsson - Managing Director, Head of Healthcare Equity Capital Markets, Morgan Stanley
Steven A. Wilcox - Partner, Ropes & Gray
Name Audience
Business Track